Chronic Urticaria
Clinical Snapshot
Urticaria is a condition characterized by the development of wheals (hives), angioedema, or both, and is a predominantly mast cell-driven disease.[1] A wheal has 3 typical features: a sharply circumscribed, central swelling of variable size and shape, almost invariably surrounded by reflex erythema; an itching or sometimes burning sensation; and a fleeting nature, with the skin returning to its normal appearance usually within 30 minutes to 24 hours.[1] Angioedema is characterized by a different set of 3 features: a sudden, pronounced, erythematous or skin-coloured deep swelling of the lower dermis and subcutis, or of mucous membranes; tingling, burning, tightness, and sometimes pain rather than itch; and a resolution that is slower than a wheal's, which can take up to 72 hours.[1]
Urticaria is classified two ways. By duration: acute urticaria is the occurrence of wheals, angioedema, or both for 6 weeks or less; chronic urticaria (CU) is the occurrence of wheals, angioedema, or both for more than 6 weeks, which can come with daily or almost-daily signs and symptoms, or with an intermittent, recurrent course over months or years.[1] By the role of a definite trigger: chronic spontaneous urticaria (CSU) — the term that has replaced "chronic idiopathic urticaria" — has no definite eliciting factor, while chronic inducible urticaria (CIndU) is provoked by a definite and specific trigger that reliably and reproducibly produces wheals, angioedema, or both when present and never when absent.[1][2] A patient can have more than one form of CU at once — CSU together with one or more CIndU subtypes are common — and each form can respond independently to treatment.[1]
CSU is not rare: Canadian data put its prevalence at roughly 0.5% to 1% of the general population, occurring most commonly in women, with a peak age of onset between 20 and 40 years.[2] Angioedema accompanies wheals in an estimated 33% to 66% of CSU patients, and 10% to 50% of patients have disease lasting longer than 5 years.[2] Chronic urticaria is genuinely disabling: it impairs quality of life and work/school performance to a degree comparable with coronary artery disease in some studies, and it carries a substantial cost burden for patients and the health system.[1] The pharmacist's highest-value contribution here is threefold: confirming the pattern really is ordinary chronic urticaria rather than one of its more serious mimics, driving a genuinely stepped pharmacotherapy ladder rather than defaulting to a sedating first-generation antihistamine, and recognizing the specific red flags — a lesion lasting more than 24 hours, or angioedema with airway involvement — that change the plan entirely.
Recognize the Condition
Chronic spontaneous urticaria (CSU)
CSU presents as spontaneous, recurring wheals, angioedema, or both, without a definite identifiable eliciting factor, for more than 6 weeks.[1] Based on current evidence, CSU itself has recognized causes even though no external trigger is identifiable: Type I autoimmunity (also called "autoallergic" CSU, driven by IgE autoantibodies against self-antigens) and Type IIb autoimmunity (driven by mast cell-activating autoantibodies, typically IgG against the IgE receptor or against IgE itself); when neither mechanism is identified, the cause is labelled unknown.[1] An autoimmune component of this kind is found in roughly 45% of CSU patients, and about 25% of CSU patients also have thyroid autoantibodies, though in CSU these do not correlate with altered thyroid function.[2]
Chronic inducible urticaria (CIndU) — 8 recognized subtypes
CIndU is characterized by definite, subtype-specific triggers that always produce wheals, angioedema, or both when present and never when absent.[1] The recognized subtypes are symptomatic dermographism (formerly urticaria factitia or dermographic urticaria), cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, and vibratory angioedema — collectively referred to as chronic physical urticaria — plus cholinergic urticaria, contact urticaria, and aquagenic urticaria.[1] Rare subtypes exist where 2 or more definite triggers must combine to provoke symptoms, for example cold-induced cholinergic urticaria.[1]
Selected CIndU subtypes
Symptomatic dermographism
Linear wheals appear within minutes where the skin is scratched, rubbed, or under friction from clothing. It can be confused with spontaneous CSU because seemingly spontaneous hives are actually caused by loose-fitting clothing rubbing on the skin or unintentional scratching.[1] Diagnosed with a dermographometer or a standardized threshold-testing device (e.g., FricTest).[1]
Cold urticaria
Wheals and sometimes angioedema develop on rewarming after cold exposure — cold air, water, or objects. Diagnosed with a cold provocation and threshold test, for example using a Peltier element-based device.[1] Swimming in cold water carries a genuine risk of a large-surface-area reaction with hypotension, so patients need explicit counselling on this.
Delayed pressure urticaria
Deep, often painful swelling develops 30 minutes to several hours after sustained pressure — from tight waistbands, shoulder straps, or standing/sitting on a hard surface. Diagnosed with a pressure test and threshold testing using graded weighted rods.[1] Patients should be counselled that pressure is force per area, so broadening the contact area of straps and bags can reduce symptoms.
Cholinergic urticaria
Small, punctate wheals with a surrounding flare erupt with or shortly after a rise in core body temperature — exercise, hot showers, spicy food, fever, or emotional stress — and in severe cases can be accompanied by facial swelling resembling angioedema. Diagnosed with exercise or heat provocation and threshold testing, for example pulse-controlled ergometry.[1]
Solar, heat, aquagenic, vibratory, and contact urticaria
Solar urticaria follows exposure to a specific wavelength of UV or visible light; heat urticaria follows direct contact with a hot object or surface; aquagenic urticaria follows skin contact with water of any temperature; vibratory angioedema follows vibration (e.g., power tools, a motorcycle, or a towel briskly dried against the skin); and contact urticaria follows direct skin contact with a specific substance. Each is diagnosed with its own subtype-specific provocation and threshold test.[1]
Angioedema
Angioedema is a sudden, deep swelling of the lower dermis, subcutis, or mucous membranes, typically involving the lips, eyelids, tongue, hands, feet, or genitalia, and sometimes the gastrointestinal mucosa, producing abdominal pain rather than a visible swelling. Unlike a wheal, it is usually not itchy — patients describe tingling, burning, tightness, or pain — and it resolves more slowly, sometimes taking up to 72 hours.[1][2] It is typically asymmetric and non-dependent.[2] Angioedema can occur together with wheals in CSU or any CIndU subtype, or it can occur in isolation, which should prompt consideration of a bradykinin-mediated cause rather than ordinary urticaria — see Red Flags & Refer.
Risk Factors
- Female sex and a peak age of onset between 20 and 40 years, though CSU occurs at any age.[2]
- An autoimmune component — Type I ("autoallergic") or Type IIb autoimmunity — identified in roughly 45% of CSU patients.[2]
- Thyroid autoantibodies, present in about 25% of CSU patients, and a personal history of another autoimmune disease.[2]
- Concomitant chronic inducible urticaria, high disease activity, an elevated CRP, and/or the presence of angioedema — each is linked to a longer expected duration of CSU and a poorer response to antihistamine treatment.[1]
- NSAID and aspirin intake as an aggravating (not causative) factor — up to 1 in 4 CSU patients has their disease activity worsened by NSAIDs, with paracetamol (acetaminophen) and/or a COX-2 inhibitor generally safer alternatives.[1]
- Stress — up to one-third of CSU patients report their disease activity is linked to stress.[1]
- Possible aggravating (not clearly causative) chronic infectious or inflammatory processes, including Helicobacter pylori-associated gastritis, other gastritis, reflux esophagitis, or nasopharyngeal bacterial infection — evidence for a causal role is inconsistent and intensive screening for infectious causes in every patient is not advised.[1]
- A family history of chronic urticaria.
- For each CIndU subtype: exposure to its specific trigger — cold air, water, or objects; sustained pressure or tight clothing; a rise in core body temperature from exercise, heat, or emotional stress; a specific light wavelength; skin contact with water; vibration; or direct skin contact with a specific substance.[1]
Red Flags & Refer
Most chronic urticaria is safely managed with the stepped pharmacotherapy ladder below. Escalate to urgent or specialist assessment instead for any of the following:
- Angioedema with airway involvement — swelling of the tongue, pharynx, or larynx, voice change, stridor, drooling, or difficulty breathing or swallowing — needs immediate emergency assessment. If wheeze, hypotension, or gastrointestinal symptoms accompany the angioedema, treat as anaphylaxis and give intramuscular epinephrine without waiting on antihistamines alone to work.
- Individual wheals lasting more than 24 hours, especially if painful or burning rather than itchy, and resolving with bruising or post-inflammatory hyperpigmentation rather than clearing completely — this pattern is far more typical of urticarial vasculitis than of ordinary chronic urticaria. In an international Delphi survey, a wheal duration of 24 hours or more was reported by 63.1% of urticarial vasculitis patients versus only 20.8% of chronic spontaneous urticaria patients, and post-inflammatory hyperpigmentation was seen in 72.6% of urticarial vasculitis patients versus 20.6% of CSU patients.[3] Obtain a lesional skin biopsy rather than continuing to escalate ordinary urticaria therapy.
- Recurrent angioedema without any wheals, particularly if it does not respond to antihistamines — consider a bradykinin-mediated cause. Review for an ACE inhibitor (remission usually occurs within days of stopping, though rarely takes up to 6 months) or, less commonly, an angiotensin receptor blocker, a DPP-4 inhibitor (gliptin), or a neprilysin inhibitor.[1] If drug-induced angioedema is excluded or there is a suggestive family history or early age of onset, test complement C4 and C1-inhibitor level and function for hereditary angioedema.[1]
- Recurrent unexplained fever, joint or bone pain, or malaise accompanying wheals — consider an autoinflammatory disease such as a cryopyrin-associated periodic syndrome or Schnitzler syndrome rather than ordinary CSU, and pursue further workup (e.g., paraproteinemia screening, genetic testing) as indicated.[1]
- No adequate response to a genuinely stepped, guideline-concordant regimen, or genuine diagnostic uncertainty at any point — refer for specialist allergy/immunology or dermatology assessment; the 3rd and 4th steps of the treatment ladder (omalizumab and cyclosporine) should be initiated and monitored under specialist supervision.[1]
Assessment & Diagnosis
History
Take a detailed history first — it is the essential first step in the diagnostic workup of every urticaria patient.[1] Ask specifically: "For how long does each individual wheal last?" (fleeting and under 24 hours points to ordinary urticaria; persisting longer points toward vasculitis) and, when a trigger is suspected, "Can you make your wheals appear? Can you bring out your wheals?"[1] Review any photographs the patient has taken, since wheals and angioedema are transient and often not present at the time of the visit.[1] Ask about pain versus itch, angioedema episodes and their distribution, systemic symptoms (fever, joint pain, malaise), a family history of angioedema or early age of onset, and current medications — specifically NSAIDs and any ACE inhibitor, angiotensin receptor blocker, gliptin, or neprilysin inhibitor.[1]
Physical examination
Examine any active wheals or angioedema for the typical features described in Recognize the Condition, and specifically look for bruising, purpura, or residual hyperpigmentation at sites of prior wheals, which is not expected in ordinary urticaria.
Recommended diagnostic tests by urticaria type
| Type | Routine tests recommended |
|---|---|
| Acute spontaneous urticaria | None, unless the history strongly suggests a specific trigger (e.g., a type I food or drug allergy). Routine diagnostic measures are specifically recommended against in acute urticaria.[1] |
| Chronic spontaneous urticaria | Differential blood count and ESR and/or CRP in all patients; in specialist care, add IgG anti-thyroid peroxidase (anti-TPO) and total IgE.[1] |
| Chronic inducible urticaria (any subtype) | Provocation testing and threshold testing specific to the subtype (see Recognize the Condition); for symptomatic dermographism, also add a differential blood count and ESR or CRP.[1] |
Further, individually selected testing — for example allergy testing, thyroid autoantibodies, an avoidance diet, or a lesional skin biopsy — is reserved for when the basic workup, history, or examination points to a specific underlying cause or an alternative diagnosis; broad, unfocused screening panels are not recommended.[1]
Differential diagnosis
| Condition | Features that point away from ordinary chronic urticaria |
|---|---|
| Urticarial vasculitis | Individual wheals lasting 24 hours or more, painful or burning rather than itchy, resolving with bruising or hyperpigmentation; vessel-wall necrosis on biopsy.[1][3] |
| Maculopapular cutaneous mastocytosis (urticaria pigmentosa) / indolent systemic mastocytosis | Fixed, pigmented lesions that urticate with rubbing (Darier's sign) rather than transient spontaneous wheals.[1] |
| Mast cell activation syndrome | Recurrent episodes with additional systemic features (flushing, GI symptoms, hypotension) and an elevated tryptase during episodes.[1] |
| Bradykinin-mediated angioedema (hereditary or ACE inhibitor-induced) | Recurrent angioedema without wheals, poor or no response to antihistamines/corticosteroids/epinephrine, possible family history.[1] |
| Exercise-induced anaphylaxis | Systemic symptoms (hypotension, wheeze, GI symptoms) specifically tied to exercise, not a chronic recurring pattern independent of exertion.[1] |
| Cryopyrin-associated periodic syndromes / Schnitzler syndrome / adult-onset Still's disease | Recurrent fever, arthralgia or arthritis, bone pain, lymphadenopathy, or monoclonal gammopathy accompanying the rash.[1] |
| Bullous pemphigoid (pre-bullous stage) | Usually an older patient; lesions evolve toward frank blistering rather than remaining urticarial.[1] |
A skin biopsy is not needed for typical, fleeting, itchy wheals, but should be obtained when any of the following are present: a wheal duration of 24 hours or more, bruising or post-inflammatory hyperpigmentation, or accompanying systemic symptoms — any one of these should guide the decision to biopsy.[3]
Scoring disease activity and control
Use validated tools at every visit rather than an unstructured impression.[1] For wheal-predominant disease, the Urticaria Activity Score (UAS7) sums a daily 0-3 wheal score and a daily 0-3 pruritus score over 7 consecutive days (maximum 42), and the Urticaria Control Test (UCT) is a 4-item, 4-week-recall tool with a cutoff of 12 out of 16 points for "well-controlled" disease.[1] For angioedema, the parallel tools are the Angioedema Activity Score (AAS), summed over 4 weeks, and the Angioedema Control Test (AECT), a 4-item tool with a cutoff of 10 out of 16 points for well-controlled disease.[1] Patients with both wheals and angioedema should be assessed with both pairs of tools.[1]
Treatment Targets
- Achieve complete symptom control — a continuous UAS7 of 0 — as safely as possible, individualized to each patient.[1]
- Search for and, where genuinely feasible, eliminate or reduce identifiable aggravating factors (NSAIDs, stress) without delaying real pharmacotherapy while doing so.[1]
- Follow the assess-adjust-act cycle at every visit: assess disease activity/control/impact with UAS7, UCT, AAS, and/or AECT; adjust by stepping up if control is inadequate, changing therapy if side effects occur, or stepping down if the patient has been symptom-free for 3-6 months; act by treating comorbidities, applying non-pharmacologic measures (especially in CIndU), and educating the patient.[1]
- Use non-sedating second-generation H1-antihistamines continuously, not on an as-needed basis, as the backbone of therapy for every urticaria type.[1]
- Minimize exposure to first-generation antihistamines and to long-term systemic corticosteroids — neither belongs in routine chronic urticaria management.[1][4]
- Track angioedema burden separately from wheal burden using the AAS and AECT, since the two do not always track together.[1]
- Restore quality of life, and screen for and address the anxiety, depression, sleep disturbance, and sexual dysfunction that commonly accompany chronic urticaria.[2]
Choose Initial Treatment
Step 1 — standard-dose 2nd-generation H1-antihistamine, for every type of urticaria
1st line, all urticaria types a standard-dosed, modern second-generation H1-antihistamine, taken continuously, not as-needed, to prevent wheals and angioedema rather than chase them after they appear.[1] Tested and effective options include bilastine, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, and rupatadine — no recommendation can be made on which one to choose first, since well-designed comparative trials are lacking.[1] Do not use 2 different second-generation antihistamines at the same time — if one agent is inadequate, updose that same agent rather than combining agents with different pharmacologic properties.[1]
Do not use a 1st-generation antihistamine (e.g., diphenhydramine, hydroxyzine) as first-line, or routinely at all, for chronic urticaria in adults or children.[4] First-generation agents cross into the CNS and carry pronounced anticholinergic and sedative effects, interfere with restful REM sleep, cause "morning-after" hangover effects, and impair learning, memory, and complex sensorimotor performance such as driving — effects that are often more pronounced than patients realize.[4] Based on strong evidence of potentially serious side effects, including reported lethal overdoses, the Canadian Society of Allergy and Clinical Immunology and the international GA²LEN position paper both recommend against using first-generation H1-antihistamines any longer for the routine management of urticaria, a position echoed by the WHO ARIA guideline.[1][4]
Step 2 — updose the same 2nd-generation antihistamine, up to 4x
2nd line if control is inadequate after roughly 2-4 weeks on a standard dose (sooner if symptoms are intolerable), increase the dose of the same second-generation antihistamine up to fourfold the standard licensed dose before moving to a different class of treatment.[1] For example: desloratadine can be increased up to 20 mg daily and cetirizine up to 40 mg daily.[4] This updosing is off-label above the standard licensed dose, but it has been recommended in urticaria guidelines since the year 2000, and no serious adverse events or long-term accumulation-related side effects have been reported in the literature to date.[1] Do not exceed 4 times the standard dose — higher doses have not been tested and are not recommended.[1]
Step 3 — add omalizumab
3rd line, specialist-supervised if control remains inadequate on an updosed second-generation antihistamine within about 6 months (sooner if symptoms are intolerable), add omalizumab 300 mg subcutaneously every 4 weeks — the licensed dose for CSU — while continuing the background antihistamine.[1] Omalizumab is an anti-IgE monoclonal antibody shown to be highly effective and safe in CSU, is also reported effective off-label in several CIndU subtypes (cholinergic, cold, solar, heat, symptomatic dermographism, and delayed pressure urticaria), markedly improves quality of life, is suitable for long-term treatment, and effectively treats relapse after a prior course is stopped.[1] Its dosing for urticaria is independent of the patient's total serum IgE, unlike its allergic asthma indication.[1] If control is still inadequate at the licensed dose, specialist-directed off-label updosing to 600 mg every 2 weeks is supported by further study data.[1]
Step 4 — add cyclosporine
4th line, specialist-supervised if control remains inadequate despite an adequate, optimized trial of omalizumab, add cyclosporine 3-5 mg/kg/day in divided doses on top of the background antihistamine.[1][2] Cyclosporine has a moderate, direct effect on mast cell mediator release and has shown efficacy in placebo-controlled trials in combination with a second-generation antihistamine, but it carries a materially less favourable adverse-effect profile than omalizumab (nephrotoxicity, hypertension) — omalizumab should be tried first specifically because of its superior safety, even though neither drug is licensed for urticaria everywhere.[1] Cyclosporine for chronic urticaria should be reserved for patients with disease refractory to any dose of antihistamine plus omalizumab in combination.[1]
Corticosteroids — rescue only, never maintenance
Do not use systemic glucocorticoids long-term for chronic urticaria — this is a strong recommendation against, not a judgment call.[1] Severe acute exacerbation a short rescue course can be considered: for example, an initial dose of 0.3-0.5 mg/kg of prednisone or equivalent, tapered by half every 3-7 days over a maximum of 2-4 weeks,[2] or, per international guidance, 20-50 mg/day prednisone-equivalent (adult dosing) for a maximum of about 10 days.[1] A short rescue course in children should be used only as a very restricted measure.[1]
The assess-adjust-act cycle
Step up if control is inadequate at any step; step down — reducing the dose or extending the interval — once the patient has been symptom-free for 3-6 months, since spontaneous remission can occur at any time and the severity of disease genuinely fluctuates.[1] Steps 3 and 4 of this ladder (omalizumab and cyclosporine) should be initiated and monitored under specialist supervision.[1]
Non-Pharmacologic Treatment
- Advise patients to discontinue any medication suspected of worsening chronic spontaneous urticaria, most commonly NSAIDs — paracetamol (acetaminophen) and/or a COX-2 inhibitor are generally safer analgesic alternatives in CSU.[1]
- For CIndU, provide clear, practical information to help patients recognize and minimize exposure to their specific trigger — for example, broadening the contact area of straps and waistbands in delayed pressure urticaria, or choosing sunscreens and light-filtering options matched to the specific provoking wavelength in solar urticaria.[1] Counsel explicitly that avoidance alone often does not fully control CIndU and can come with a real quality-of-life cost — patients with cholinergic urticaria who abstain from physical exercise, or with solar urticaria who avoid being outdoors, can become markedly more impaired by the avoidance than by the disease itself.[1]
- Tolerance induction (rush hardening) can help in some CIndU subtypes, notably cold, cholinergic, and solar urticaria — for example, a rush ultraviolet-A regimen has been reported effective within 3 days for some patients.[1] However, the induced tolerance typically lasts only a few days, so consistent daily exposure to the trigger at threshold level is required to maintain it, and many patients do not accept or tolerate this long-term.[1]
- A pseudoallergen-free or low-histamine diet is controversial and unproven in well-designed double-blind placebo-controlled studies; if trialled, maintain it for only 2-3 weeks before assessing benefit, and do not let a diet trial delay effective pharmacotherapy.[1]
- Screen for and address the psychosocial burden of chronic urticaria directly — anxiety, depression, sleep disturbance, and sexual dysfunction are all common consequences, and stress itself can be a genuine aggravating factor for CSU activity.[2][1]
- Do not order intensive, costly general screening programs "to find the cause" in every chronic urticaria patient — this is specifically advised against; testing should be guided by history, examination, and basic labs rather than performed reflexively.[1]
- Educate every patient on the difference between isolated urticaria/angioedema and true anaphylaxis, and on when epinephrine and emergency care — not just an antihistamine — are needed.
Special Populations
Pregnancy
Preferred antihistamine loratadine is generally preferred in pregnancy, extrapolating from the larger available safety experience with its active metabolite desloratadine and with cetirizine; to date, no reports of birth defects have been linked to modern second-generation H1-antihistamine use in pregnancy, though only small studies are available for cetirizine and one larger meta-analysis for loratadine.[1] Avoid first-generation antihistamines in pregnancy.[1] Updosing above the standard dose in pregnancy can only be carefully suggested case by case, since safety studies at higher doses have not been done.[1] Omalizumab use in pregnancy has been reported as safe to date with no indication of teratogenicity, but reserve it for genuine need.[1] Cyclosporine is not teratogenic but is embryo-toxic in animal models and is associated with preterm delivery and low birth weight in human infants — whether its benefits are worth the risks in a pregnant patient must be judged case by case.[1] Avoid long-term systemic corticosteroids; a short rescue course should be reserved for genuine need under specialist guidance.
Breastfeeding
Second-generation H1-antihistamines are excreted into breast milk in low concentrations and their use is generally advised, with loratadine again preferred given the largest safety experience; note that loratadine is metabolized in the liver, which is not the case for its metabolite desloratadine.[1] Avoid first-generation antihistamines in lactation — nursing infants can develop sedation from first-generation agents transmitted through breast milk.[1] Omalizumab has been reported safe in lactation to date.[1]
Children
Second-generation H1-antihistamines with demonstrated efficacy and safety in the pediatric population include bilastine, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, and rupatadine — the choice depends partly on the licensed lowest age and available formulation (syrup versus fast-dissolving tablet) in a given country, since modern second-generation agents are often not licensed below 6 months of age.[1] Do not reach for a first-generation antihistamine as first-line in children despite it being common practice in some settings — it has an inferior safety profile compared with second-generation agents and is not recommended.[1] The same stepped algorithm is suggested in children, used with caution and weight-adjusted dosing; updosing and the later steps of the ladder are not well studied in this age group and further treatment decisions should be individualized.[1] A short corticosteroid course, when genuinely needed, should be used only as a very restricted measure in children.[1]
Older adults
Age itself does not change the recommended ladder, but it sharply raises the stakes of choosing a first-generation antihistamine — anticholinergic burden, sedation, falls, and cognitive impairment are all disproportionately harmful in this group, reinforcing that second-generation agents are the appropriate choice from the outset. Dose-adjust renally cleared agents (cetirizine, levocetirizine, fexofenadine) for reduced renal function, and monitor more closely for cyclosporine-related nephrotoxicity and hypertension given age-related decline in renal reserve.
Autoimmune-associated CSU
Consider thyroid function and autoantibody testing in specialist care given the roughly 25% prevalence of thyroid autoimmunity in CSU.[2] Direct reduction of functional autoantibodies by plasmapheresis has shown temporary benefit in some severely affected, treatment-unresponsive, autoantibody-positive patients, but experience and evidence are limited and cost is high — this remains a specialist-only, last-resort option.[1]
Renal impairment
Dose-adjust cetirizine, levocetirizine, and fexofenadine for reduced renal function. Cyclosporine is nephrotoxic — use with particular caution and close monitoring in any degree of renal impairment.
Hepatic impairment
Desloratadine and loratadine are hepatically metabolized; use with caution in significant hepatic impairment. Cyclosporine is metabolized via CYP3A4 — monitor liver function and screen carefully for interacting drugs.
Monitoring & Follow-Up
Common Errors to Avoid
- Reaching for a first-generation antihistamine as first-line "because it works faster or stronger" — second-generation agents are the recommended first-line for every type of urticaria, and first-generation agents add anticholinergic, sedative, and cognitive risk without a demonstrated efficacy advantage.[4]
- Combining 2 different second-generation antihistamines together instead of updosing a single agent — this is specifically recommended against.[1]
- Jumping straight to omalizumab or cyclosporine without first trialling updosing the second-generation antihistamine to 4x standard dose.[1]
- Using cyclosporine before an adequate trial of omalizumab, given cyclosporine's inferior safety profile.[1]
- Treating a patient whose individual wheals last more than 24 hours and leave bruising as simply "refractory" chronic urticaria rather than obtaining a lesional skin biopsy for urticarial vasculitis.[3]
- Missing recurrent angioedema without wheals as bradykinin-mediated (ACE inhibitor or hereditary) and treating it with antihistamines or omalizumab, neither of which works for bradykinin-mediated swelling.[1]
- Continuing systemic corticosteroids long-term for "maintenance" control — a strong recommendation against; reserve for brief rescue courses only.[1]
- Ordering an extensive, costly diagnostic screening panel in every new chronic urticaria patient rather than the limited, guideline-directed basic tests.[1]
- Delaying real pharmacotherapy for a prolonged empiric pseudoallergen-free or low-histamine diet trial.[1]
- Leaving a patient on escalated therapy (updosed antihistamine, omalizumab, or cyclosporine) indefinitely rather than reassessing for step-down every 3-6 months once they are symptom-free.[1]
- Missing that ongoing NSAID use — aspirin included — may be an aggravating factor for up to 1 in 4 CSU patients, with paracetamol or a COX-2 inhibitor as safer analgesic alternatives.[1]
Clinical Decision Algorithm
Drug Tables
Second-Generation H1-Antihistamines (Non-Sedating) — First-Line for All Urticaria Types
Taken continuously, not as-needed. If a standard dose is inadequate after 2-4 weeks, updose the SAME agent up to 4x rather than switching or combining agents.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cetirizine | Standard: 10 mg PO once daily Updosed (up to 4x): Up to 40 mg PO once daily | Mild sedation/headache, more likely at updosed levels; dry mouth | Minimal — largely renally cleared, not a CYP substrate | Standard dose 10 mg once daily; updosed examples 20/30/40 mg once daily. |
| Desloratadine | Standard: 5 mg PO once daily Updosed (up to 4x): Up to 20 mg PO once daily | Headache, fatigue, dry mouth | None clinically significant at standard doses | Standard dose 5 mg once daily; up to 20 mg once daily reported effective when updosed. |
| Fexofenadine | Standard: 180 mg PO once daily Updosed (up to 4x): Up to 720 mg/day, in divided doses | Headache, mild sedation uncommon at standard dose | Aluminum/magnesium antacids and fruit juices reduce absorption — separate dosing by 2 hours | Standard dose 180 mg once daily; updose up to 4x under specialist guidance if inadequate. |
| Loratadine | Standard: 10 mg PO once daily Updosed (up to 4x): Up to 40 mg/day, in divided doses | Headache, dry mouth, fatigue | Hepatically metabolized — use with caution in significant hepatic impairment | Preferred agent in pregnancy and lactation given the largest published safety experience. |
| Bilastine | Standard: 20 mg PO once daily Updosed (up to 4x): Up to 80 mg PO once daily | Headache, mild somnolence uncommon at standard dose | Take on an empty stomach — food reduces absorption; avoid with ketoconazole/erythromycin | Standard dose 20 mg once daily; updosing to 80 mg/day is supported by trial evidence. |
| Rupatadine | Standard: 10 mg PO once daily Updosed (up to 4x): Up to 40 mg PO once daily | Headache, somnolence, fatigue | Avoid with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) — increased exposure | Standard dose 10 mg once daily; updosing to 40 mg/day is supported by trial evidence. |
| Levocetirizine | Standard: 5 mg PO once daily Updosed (up to 4x): Up to 20 mg PO once daily | Mild sedation/headache, more likely at updosed levels | Minimal — largely renally cleared, not a CYP substrate | Standard dose 5 mg once daily; updosing to 20 mg/day is supported by trial evidence. |
First-Generation H1-Antihistamines — Not Recommended for Routine Use
Listed to state explicitly why these should not be first-line, or routine, choices for chronic urticaria at any age — not as an alternative option.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Diphenhydramine | Not recommended for routine chronic urticaria management: — | Prominent sedation, anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation), impaired REM sleep and next-day cognition, paradoxical excitation in children/older adults, rare serious/lethal overdose | Additive CNS/respiratory depression with opioids, benzodiazepines, and alcohol; additive anticholinergic burden with other anticholinergic drugs, especially in older adults | CSACI and the international GA²LEN position paper recommend against routine use in urticaria at any age — a 2nd-generation agent gives equal or better control without this risk profile. |
| Hydroxyzine | Not recommended for routine chronic urticaria management: — | Prominent sedation, anticholinergic effects, QT prolongation at higher exposure, impaired REM sleep and next-day cognition | Additive CNS/respiratory depression with other sedatives; additive QT effect with other QT-prolonging drugs | Same rationale as diphenhydramine — not recommended as routine or first-line therapy for chronic urticaria. |
Anti-IgE Biologic — Third-Line Add-On
Initiate and monitor under specialist supervision. Continue the background 2nd-generation antihistamine alongside it.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Omalizumab | Licensed dose: 300 mg SC every 4 weeks Specialist-directed updosing if inadequate: Up to 600 mg SC every 2 weeks (off-label) | Injection-site reactions (most common); headache, arthralgia; anaphylaxis (rare) — observe patients appropriately around dosing per the product monograph | None clinically significant reported | Licensed dose for CSU is independent of total serum IgE. Also reported effective off-label in several CIndU subtypes. Suitable for long-term use; relapse after stopping typically responds again to re-initiation. |
Immunosuppressant — Fourth-Line Add-On
Reserve for disease refractory to antihistamine plus omalizumab in combination. Off-label for urticaria. Initiate and monitor under specialist supervision.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cyclosporine | Dosing: 3-5 mg/kg/day PO in divided doses (twice daily) | Nephrotoxicity, hypertension, hepatotoxicity, hirsutism, gingival hyperplasia, tremor, increased infection risk with prolonged use | Extensive CYP3A4/P-glycoprotein substrate — azole antifungals, macrolides, and grapefruit juice raise levels; rifampin and anticonvulsants lower levels; avoid live vaccines during use | A far less favourable safety profile than omalizumab — try omalizumab first. Check baseline and periodic blood pressure and renal function. |
Short-Course Corticosteroid — Acute Severe Exacerbation Only
Never for long-term or maintenance use in chronic urticaria — this is a strong recommendation, not a judgment call.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Prednisone | Adult, brief rescue course: 20-50 mg/day equivalent for up to about 10 days Alternative tapering schedule: 0.3-0.5 mg/kg initial dose, tapered by half every 3-7 days over 2-4 weeks total | Hyperglycemia, insomnia, mood change, GI upset; osteoporosis, adrenal suppression, and weight gain if misused as maintenance therapy | Increased GI bleeding risk with NSAIDs; may reduce vaccine efficacy | Reserve for a brief rescue course during a severe acute flare while stepping up maintenance therapy — not itself a maintenance option. |
Adjunctive / Low-Evidence Option
Not part of the core 4-step ladder. Listed because it is sometimes used as an adjunct, with the evidence quality made explicit.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Montelukast | Adult: 10 mg PO once daily | Headache, GI upset; rare neuropsychiatric effects | Minimal clinically significant interactions | Best supporting evidence is specifically in NSAID/aspirin-sensitive urticaria; overall evidence quality for benefit in chronic urticaria is low. |
Emergency Treatment — Airway-Threatening Angioedema or Anaphylaxis
Use without hesitation whenever anaphylaxis criteria are met alongside urticaria or angioedema — an antihistamine alone is not adequate for an airway emergency. See the Anaphylaxis chapter for full management.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Epinephrine | Adult standard dose: 0.3 mg IM Pediatric standard dose: 0.15 mg IM Weight-based alternative: 0.01 mg/kg IM to a maximum of 0.5 mg | Tachycardia, anxiety, tremor, headache | Additive cardiovascular effects with other sympathomimetics; caution with MAO inhibitors and tricyclic antidepressants | IM autoinjector into the anterolateral thigh; repeat every 5-15 minutes as needed if symptoms persist. |
References
- The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria — Allergy (Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al.; Canadian delegates Sussman G, Hébert J, nominated by the Canadian Society of Allergy and Clinical Immunology). Allergy 2022;77(3):734-766
- Insights and advances in chronic urticaria: a Canadian perspective — Allergy, Asthma & Clinical Immunology (Sussman G, Hébert J, Gulliver W, et al.). Allergy Asthma Clin Immunol 2015;11:7
- Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey — Clinical and Translational Allergy (Krause K, Bonnekoh H, Jelden-Thurm J, et al.). Clin Transl Allergy 2023;13(10):e12305
- CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria — Allergy, Asthma & Clinical Immunology (Fein MN, Fischer DA, O'Keefe AW, Sussman GL). Allergy Asthma Clin Immunol 2019;15:61
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.